نتایج جستجو برای: anthracyclines

تعداد نتایج: 3200  

Journal: :Cancer genomics & proteomics 2007
Lionel Apetoh Michel Obeid Antoine Tesniere François Ghiringhelli Gian Maria Fimia Mauro Piacentini Guido Kroemer Laurence Zitvogel

The aim of chemotherapy and radiotherapy is to eliminate tumor cells. While the outcomes of these cytotoxic treatments have previously been assigned to their direct effects on tumor cells, recent findings have shown that the host's immune system also contributes to the success of chemotherapeutic and radiotherapeutic regimens. The finding that some cytotoxic antitumor coumpounds such as anthrac...

2013
Baoxu Pang Xiaohang Qiao Lennert Janssen Arno Velds Tom Groothuis Ron Kerkhoven Marja Nieuwland Huib Ovaa Sven Rottenberg Olaf van Tellingen Jeroen Janssen Peter Huijgens Wilbert Zwart Jacques Neefjes

DNA topoisomerase II inhibitors are a major class of cancer chemotherapeutics, which are thought to eliminate cancer cells by inducing DNA double-strand breaks. Here we identify a novel activity for the anthracycline class of DNA topoisomerase II inhibitors: histone eviction from open chromosomal areas. We show that anthracyclines promote histone eviction irrespective of their ability to induce...

Journal: :Cancer research 1993
L C Papadopoulou A S Tsiftsoglou

Daunomycin and other structurally related anthracyclines can cause myelosuppression and cardiomyopathy. We explored the possible mechanism(s) by which daunomycin (DAU) interacts with target sites in neoplastic hemopoietic cells and heart tissue. We observed that [3H(G)]DAU interacts selectively with mitochondrial hemoproteins isolated from K-562 cells and rat and bovine heart and forms relative...

2013
B. Haibe-Kains C. Desmedt A. Di Leo E. Azambuja D. Larsimont J. Selleslags S. Delaloge C. Duhem J.P. Kains B. Carly M. Maerevoet A. Vindevoghel G. Rouas F. Lallemand V. Durbecq F. Cardoso R. Salgado R. Rovere G. Bontempi S. Michiels M. Buyse J.M. Nogaret Y. Qi F. Symmans L. Pusztai V. D'Hondt M. Piccart-Gebhart C. Sotiriou

Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-alpha (TOP2A) and develop a gene expr...

2009
Karin Jordan Timo Behlendorf Franziska Mueller Hans-Joachim Schmoll

Correspondence: Karin Jordan Clinic for internal Medicine iv, Department for Oncology and Haematology, University Hospital Halle, ernst-Grube-Str. 40, 06120 Halle (Saale), Germany Tel +49 (0) 345/557-2924 Fax +49 (0) 345/557-2950 email [email protected] Abstract: The application of anthracyclines in anticancer therapy may result in accidental extravasation injury and can be a se...

2011
Wawaimuli Arozal Flori R. Sari Kenichi Watanabe Somasundaram Arumugam Punniyakoti T. Veeraveedu Meilei Ma Rajarajan A. Thandavarayan Vijayakumar Sukumaran Arun Prasath Lakshmanan Yoshiyasu Kobayashi Sayaka Mito Vivian Soetikno Kenji Suzuki

Anthracyclines, most powerful anticancer agents, suffer from their cardiotoxic effects, which may be due to the induction of oxidative stress. Carvedilol, a third-generation, nonselective β-adrenoreceptor antagonist, possesses both reactive oxygen species (ROS) scavenging and ROS suppressive effects. It showed protective effects against daunorubicin- (DNR-) induced cardiac toxicity by reducing ...

Journal: :Immunity 2013
Nuno Figueiredo Angelo Chora Helena Raquel Nadja Pejanovic Pedro Pereira Björn Hartleben Ana Neves-Costa Catarina Moita Dora Pedroso Andreia Pinto Sofia Marques Hafeez Faridi Paulo Costa Raffaella Gozzelino Jimmy L Zhao Miguel P Soares Margarida Gama-Carvalho Jennifer Martinez Qingshuo Zhang Gerd Döring Markus Grompe J Pedro Simas Tobias B Huber David Baltimore Vineet Gupta Douglas R Green João A Ferreira Luis F Moita

Severe sepsis remains a poorly understood systemic inflammatory condition with high mortality rates and limited therapeutic options in addition to organ support measures. Here we show that the clinically approved group of anthracyclines acts therapeutically at a low dose regimen to confer robust protection against severe sepsis in mice. This salutary effect is strictly dependent on the activati...

2018
Timothy M Markman Maurie Markman

The therapeutic options available to treat a wide range of malignancies are rapidly increasing. At the same time, the population being treated is aging with more cardiovascular risk factors, comorbid conditions, and associated poor cardiac reserve. Both traditional chemotherapeutic agents (for example, anthracyclines) and newer therapies (for example, targeted tyrosine kinase inhibitors and imm...

Journal: :Oncology 2009
Maysa M Abu-Khalaf Lyndsay Harris

In the current issue of ONCOLOGY, Hershman and Shao provide a comprehensive review of anthracycline-induced cardiotoxicity (AIC). Risk factors for AIC include age (≤ 18 or ≥ 65 years) at time of treatment, increasing cumulative dose or dose intensity of anthracyclines, mediastinal radiation therapy (RT), and female gender.[1-4] The Surveillance, Epidemiology and End Results (SEER)-Medicare data...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید